Physician profile
Naveen Gupta
NPI 1619138104
$7,855.42
in general payments reported to CMS, 2019-2025
44 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $563 · 2021: $979 · 2022: $1,053 · 2023: $1,713 · 2024: $1,320 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,299 · Education: $20.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,298.50 |
| Education | $20.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,874.34 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,141.26 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $727.74 | 2019-2025 | Entyvio, Gattex, Glassia |
| Janssen Biotech, INC. | $673.71 | 2019-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $417.74 | 2020-2023 | |
| Pfizer INC. | $356.96 | 2019-2025 | |
| Qol Medical, LLC | $354.94 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $213.59 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $179.69 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Regeneron Healthcare Solutions, INC. | $167.59 | 2020-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $154.11 | 2019-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $143.84 | 2019-2023 | Rebyota |
| Genzyme Corporation | $124.71 | 2022-2025 | |
| Redhill Biopharma INC. | $120.63 | 2020-2024 | Talicia |
| Celltrion USA INC. | $104.23 | 2024-2025 | Vegzelma, Zymfentra |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.